ArticleNPJ vaccines2025
Maternal vaccination with live-attenuated Rift Valley fever virus protects offspring via immune transfer.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rift Valley fever virus (RVFV) causes high rates of spontaneous abortions and neonatal mortality in ruminants resulting in severe socioeconomic and public health consequences. Maternal vaccination may protect pregnant animals, fetuses, and neonates via transfer of maternal antibodies; however, currently available live-attenuated RVFV vaccines are generally unsafe for use during pregnancy. RVFV-delNSs/NSm is a live attenuated strain that has demonstrated favorable safety and efficacy in pregnant livestock, yet studies investigating maternal vaccination as a strategy to protect neonates from RVF are limited. Using pregnant Sprague-Dawley rats, we show that maternal vaccination with RVFV-delNSs/NSm leads to efficient transfer of anti-RVFV antibodies to offspring. These offspring were completely protected from lethal RVFV challenge. Although further investigation is required in susceptible ruminant species, our findings indicate that maternal anti-RVFV immunity is sufficient to protect offspring, highlighting maternal vaccination as a potential strategy to reduce RVF disease burden in endemic regions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.